Table 1 In vitro studies on efficacy of NHC (Active component of Molnupiravir) against highly pathogenic Coronaviruses (MHV-A59, MERS-CoV, SARS-CoV, and SARS-CoV-2)
From: Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
S. no. | Drug molecule | Cell line | Virus | IC50 & EC 50 | References |
|---|---|---|---|---|---|
1. | EIDD-1931 | Murine astrocytoma delayed brain tumor cells | Coronavirus MHV-A59 | EC50 = 0.17 μM | Agostini et al. (2019) |
2. | EIDD-1931 | Vero cells | MERS-CoV | EC50 = 0.56 μM | Agostini et al. (2019) |
3. | EIDD-1931 | Calu-3 2B4 | MERS-CoV | IC50 of 0.15 μM | Sheahan et al. (2020) |
4. | EIDD-1931 | Vero E6 Cells | SARS-CoV-2 | IC50 of 0.3 μM | Sheahan et al. (2020) |
5. | EIDD-1931 | Calu-3 | SARS-CoV-2 | IC50 of 0.09 μM | Sheahan et al. (2020) |
6. | EIDD-1931 | HAE | SARS-CoV-2 | Â | Sheahan et al. (2020) |
7. | EIDD-1931 | HAE | MERS-CoV | IC50 = 0.024 μM | Sheahan et al. (2020) |
8. | EIDD-1931 | HAE | SARS-CoV | IC50 = 0.14 μM | Sheahan et al. (2020) |
9. | EIDD-2801 | Calu-3 | SARS-CoV-2 | IC50 = 414.6 nM | Rosenke et al. (2021) |